Zurück zur Hauptseite

Unternehmen auf Beobachtungsliste setzen

Cardiol Therapeutics

ISIN: CA14161Y2006

WKN: A2PA9E

Über

Snapshot Unternehmen

Neu: Benachrichtigung aktivieren

Aktuelle Nachrichten per Alarm empfangem

Neu: KI-Factsheet

Coming soon: Zusammenfassung der Unternehmensnachricht durch KI/p>

Cardiol Therapeutics · ISIN: CA14161Y2006 · Newswire (Unternehmen)

Land: Vereinigte Staaten von Amerika · Primärmarkt: Kanada · EQS NID: 1515789

Levermann Score

16 Dezember 2022 18:26PM

Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

EQS-News: Cardiol Therapeutics
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

16.12.2022 / 18:26 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

News Source: News Direct

16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Cardiol Therapeutics


	United States
ISIN:	CA14161Y2006
EQS News ID:	1515789


End of News	EQS News Service

1515789 16.12.2022 CET/CEST

Research & Analysen